AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05122169
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
Trial: NCT05122169
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
Trial: NCT05667376
Drug: curcumin gel
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: curcumin gel
Trial: NCT05311189
Drug: HLX10, Trastuzumab and Chemotherapy
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: HLX10 4.5mg/kg, IV, q3weeks, Day 1 trastuzumab 6mg/kg (8mg loading dose), IV, q3weeks, Day 1 S1 40mg/m2, PO, BID, Day 1-14 oxaliplatin 100mg/m2, IV, q3weeks, Day 1 docetaxel 40mg/m2, IV, q3weeks, Day 1
Trial: NCT06392854
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 dose insulin infusion 4 hours
Trial: NCT06213077
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasodilator which treats erectile dysfunction and enlarged prostate (benign prostatic hyperplasia). It can also treat high blood pressure in the lungs (pulmonary arterial hypertension).
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07328948 will be administered as oral suspensions daily (QD) over 14 days
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07328948 will be administered as oral suspensions every QD over 14 days
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07328948 will be administered as oral suspensions QD over 14 days
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Trial: NCT05807490
Drug: PF-07328948
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition
Trial: NCT06134037
Drug: Aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be observationally included in the Aminophylline or not Aminiophylline group depending on anesthesiologist's discretion.
Trial: NCT05487950
Drug: Rivaroxaban group
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients assigned in the Rivaroxaban group will receive 15 mg once day or 10 mg if dosage modification is needed due to renal insufficiency (Creatinine clairance calculated with the Cockroft formula between 30 or 49 ml/min).
Trial: NCT00002019
Drug: Amphotericin B, Lipid-based
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002019
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05293119
Drug: JAK-2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this trial, one group will receive the tofacitinib 5 mg twice daily
Trial: NCT05464979
Drug: Esketamine Hydrochloride 28 Mg in 0.2 mL NASAL SOLUTION [Spravato]
RxNorm normalized name: ESKETAMINE HYDROCHLORIDE 28 mg in 0.2 mL NASAL SOLUTION [Spravato]
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esketamine at 0.5-1.0 mg/kg BW and rocuronium bromide at 0.6 mg/kg BW was given intravenously for induction intubation. After the intubation was completed, esketamine was continuously pumped at 0.3-1.5 mg/kg/h to maintain sedation.
Trial: NCT04747470
Drug: GS-3583
RxNorm normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as an intravenous (IV) infusion
Trial: NCT04747470
Drug: Zimberelimab
RxNorm normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT04747470
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT04747470
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as an IV infusion
Trial: NCT04747470
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as an IV infusion
Trial: NCT04747470
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion
Trial: NCT06399835
Drug: Enavogliflozin
RxNorm normalized name: Enavogliflozin
DrugBank: Enavogliflozin (DB18970)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enavogliflozin 0.3mg once daily
Trial: NCT06399835
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15mg once daily
Trial: NCT05638126
Drug: HRS-1780 table or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HRS-1780 table or placebo single dose
Trial: NCT05638126
Drug: HRS-1780 table or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HRS-1780 table or placebo single dose with food effect
Trial: NCT05638126
Drug: HRS-1780 table or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HRS-1780 table or placebo multiple dose
Trial: NCT04728802
Drug: Proxalutamide
RxNorm normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proxalutamide 300mg q.d
Trial: NCT05782777
Drug: ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg)
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The initial dose of lipid-lowering therapy will be ezetimibe 10mg plus atoravastatin 40mg. During follow-up, the dose of ezetimibe 10mg plus atoravastatin 40mg is strongly recommended to be maintained.
Trial: NCT05877872
Drug: Adjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab(240 mg d1) continually applied since 1-2 weeks after surgery until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, investigator decision, or 1 year.
Trial: NCT05969899
Drug: FOLFIRI+Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: irinotecan liposome 60 mg/m2, iv, for at least 90 minutes LV 400 mg/m2, iv, for at least 2 hours FU 400 mg/m2, iv, followed by FU 2400 mg/m2, iv for at least 46 hours bevacizumab 5mg/kg IV. The above scenario is repeated every two weeks. Patients were treated until disease progression, toxic intolerance, initiation of a new antitumor therapy, withdrawal of knowledge, or investigator judgment that subjects should withdraw from study therapy.
Trial: NCT00849238
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04656600
Drug: Cerezyme® / Imiglucerase
DrugBank: Imiglucerase (DB00053)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
Trial: NCT00002156
Drug: Fomivirsen sodium
RxNorm normalized name: Fomivirsen Sodium
DrugBank: Fomivirsen (DB06759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002156
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04910594
Drug: recombinant human erythropoietin
RxNorm normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine the efficacy and safety of recombinant human erythropoietin in improving anemia in patients with lymphoma, and to improve the quality of life and the efficacy of chemotherapy in patients with lymphoma.
Trial: NCT05582798
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride 09.% intravenous infusion
Trial: NCT04967573
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 20 mg or 10 mg for 3 months
Trial: NCT00115414
Drug: pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00115414
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06239727
Drug: PD-1 blocking antibody
RxNorm normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.
Trial: NCT06239727
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.
Trial: NCT06239727
Drug: Cisplatin (80 mg/m2)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.
Trial: NCT06239727
Drug: Cisplatin (100 mg/m2)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Trial: NCT05192239
Drug: THC 5
RxNorm normalized name: THC
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 milligrams of THC in gummy form
Trial: NCT00054795
Drug: Motexafin Gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05460338
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: native form of Vitamin D.
Trial: NCT05344495
Drug: midazolam group
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%
Trial: NCT00000814
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000814
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000814
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000929
Drug: Nonoxynol-9
RxNorm normalized name: Nonoxynol-9
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04908592
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive dexamethasone 8 mg diluted in 100 ml 0.9% normal saline (NS) IVI over 15 min 2 h preoperatively.
Trial: NCT05839314
Drug: Renin-angiotensin-aldosterone system inhibitors (RASI)
DrugBank: Aldosterone (DB04630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run-in period: All the patients should be treated with RASI for at least 4 weeks, and stop using any medicine containing Huaier or similar ingredients for at least 2 weeks before enrollment. If the patient is receiving RASI, the RASI can be continued until the end of the study. RASI can be adjusted once a week until the maximum tolerable dose based on albuminuria and blood pressure. If the patient is not receiving RASI therapy, then RASI is recommended.~Treatment period: RASI therapy is continued throughout the trial. Check blood pressure twice daily: morning and evening.
Trial: NCT04898699
Drug: Tenofovir (300mg)/Emtricitabine(200mg) [Truvada®]
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Information will be provided regarding dosing of PrEP medications, importance of daily adherence, importance of frequent HIV testing, and signs and symptoms of drug toxicity, acute HIV infection and STIs. An initial one-month supply (30 pills) of FTC/TDF will be given to all PrEP study participants. At the one-month study assessment, a two-month supply of daily oral FTC/TDF will be given to each participant, after HIV testing, assessment for acute HIV infection and review of side effects and adherence, following national guidelines and procedures for PrEP services. At Month 3 assessment, a three-month supply of oral FTC/TDF will be given.
Trial: NCT03717181
Drug: Lixivaptan
RxNorm normalized name: Lixivaptan
DrugBank: Lixivaptan (DB06666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of lixivaptan optimized using a predetermined titration protocol.
Trial: NCT05580250
Drug: Iohexol
RxNorm normalized name: Iohexol
DrugBank: Iohexol (DB01362)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV).
Trial: NCT05580250
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally.
Trial: NCT05056116
Drug: Surufatinib Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Toripalimab injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.
Trial: NCT05314231
Drug: ALXN1720
RxNorm normalized name: IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
DrugBank: Gefurulimab (DB18928)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled participants will receive a single dose of ALXN1720 on Day 1 followed by a Post-treatment and Follow-up Period (92 days).
Trial: NCT04757974
Drug: Fostemsavir 600 mg
RxNorm normalized name: fostemsavir 600 MG
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir tablets will be administered via oral route.
Trial: NCT04757974
Drug: Fostemsavir 200 mg
RxNorm normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostemsavir tablets will be administered via oral route.
Trial: NCT05215951
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration
Trial: NCT05422001
Drug: low dose ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose ketamine 0.1 mg/kg Product: Esketamin Orifarm 5 mg/ml
Trial: NCT06044142
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin and low laser therapy will be used on patients undergoing chemotherapy
Trial: NCT04782076
Drug: Dabigatran
RxNorm normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04782076
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT05765500
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Gonadotropin-releasing hormone (GnRH) antagonist, oral tablet taken 1x daily.
Trial: NCT05765500
Drug: Leuprolide
RxNorm normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) antagonist, intramuscular injection 1x every 3 months.
Trial: NCT05416840
Drug: Clonidine controlled-release patch
RxNorm normalized name: clonidine Extended Release Suspension
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled patients receive clonidine patch (2.5 mg), once a week. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).
Trial: NCT05416840
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enrolled patients receive amlodipine (5 mg), once daily. The doses are doubled, if the office systolic BP not at goal (\<140 mmHg) at 4 weeks.~All patients receive smoking cessation advice at the beginning, and smoking cessation promotion information is pushed by WeChat three times during the observation period (weeks 2, 4 and 6).
Trial: NCT06178627
Drug: Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different amphotericin B dosage
Trial: NCT06178627
Drug: Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks.
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different amphotericin B dosage
Trial: NCT05717569
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: o Fibroscan: as a non-invasive imaging study for measuring liver cirrhosis by transducer probe-induced elastic share wave that propagates through liver tissue to measure its velocity. It is a promising non-invasive method for detection of cirrhosis in patients with chronic liver disease. Therefore, fibroscan can be used regarding the decision of treatment and follow-up of patients with cirrhosis for screening and detection of the complications . In our study the investigators will assess liver fibrosis before and after vitamin D therapy using fibroscan.
Trial: NCT05615727
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mcg/kg of undiluted dexmedetomidine \[= 0.02 ml/kg\] and oral placebo tablet
Trial: NCT05615727
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zolpidem 10 mg and intranasal saline 0.02 ml/kg
Trial: NCT05373108
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan is a nonselective endothelin-receptor antagonist (ERA) that is approved for use in pulmonary arterial hypertension (PAH); the use of Macitentan in post-heart transplant patients is considered investigational.
Trial: NCT06265454
Drug: low dose atropine eye drops
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine is a nonselective muscarinic antagonist used for myopia control in previous studies.
Trial: NCT04053621
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants will continue taking metformin in their previous established tolerated dose for the duration of the study
Trial: NCT06020911
Drug: Theracal light cured
RxNorm normalized name: kaolin light
DrugBank: Kaolin (DB01575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 primary second molars of 17 children will be capped with Theracal light cured
Trial: NCT05059873
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 40mg/day for five consecutive days
Trial: NCT05966584
Drug: Benralizumab
RxNorm normalized name: Benralizumab
DrugBank: Benralizumab (DB12023)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Benralizumab 30mg subcutaneously on day -1.
Trial: NCT04009759
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adult patients with an in-hospital cardiac arrest will be evaluated by anaesthesiologists for inclusions criteria to the study and randomised to get the blinded study medicine as addition to standard treatment of cardiac arrest. Randomization will be performed by means of sealed envelopes containing number of syringe that will be used.